Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for United Therapeutics (UTHR) over the last 17 years, with Q3 2025 value amounting to $39.1 million.

  • United Therapeutics' Share-based Compensation fell 623.5% to $39.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $135.7 million, marking a year-over-year increase of 157.19%. This contributed to the annual value of $144.0 million for FY2024, which is 26828.64% up from last year.
  • United Therapeutics' Share-based Compensation amounted to $39.1 million in Q3 2025, which was down 623.5% from $37.8 million recorded in Q2 2025.
  • United Therapeutics' 5-year Share-based Compensation high stood at $65.5 million for Q2 2022, and its period low was -$21.1 million during Q1 2022.
  • Over the past 5 years, United Therapeutics' median Share-based Compensation value was $29.1 million (recorded in 2021), while the average stood at $28.3 million.
  • In the last 5 years, United Therapeutics' Share-based Compensation crashed by 15261.85% in 2022 and then skyrocketed by 97916.67% in 2023.
  • Over the past 5 years, United Therapeutics' Share-based Compensation (Quarter) stood at $44.7 million in 2021, then skyrocketed by 44.97% to $64.8 million in 2022, then tumbled by 74.38% to $16.6 million in 2023, then surged by 62.65% to $27.0 million in 2024, then soared by 44.81% to $39.1 million in 2025.
  • Its last three reported values are $39.1 million in Q3 2025, $37.8 million for Q2 2025, and $31.8 million during Q1 2025.